Should Canadian patients look forward to aducanumab for Alzheimer disease?

In Canada, 190,000 people are living with mild Alzheimer-type dementia and 532,000 to 799,000 people are living with amnestic mild cognitive impairment. Developing treatments for Alzheimer disease is challenging, with few effective therapies that only target symptoms. Although the US Food and Drug A...

Full description

Saved in:

Bibliographic Details
Published in:	Canadian Medical Association journal (CMAJ) Vol. 193; no. 36; pp. E1430 - E1431
Main Authors:	Watt, Jennifer A, Marple, Roger, Hemmelgarn, Brenda, Straus, Sharon E
Format:	Journal Article
Language:	English
Published:	Canada CMA Joule Inc 13-09-2021 CMA Impact, Inc
Subjects:	Alzheimer Disease - drug therapy Alzheimer Disease - prevention & control Alzheimer's disease Antibodies, Monoclonal, Humanized - therapeutic use Biological products industry Canada Clinical outcomes Clinical trials Cognitive ability Dementia Dose-Response Relationship, Drug Drug dosages Drug therapy FDA approval Humans Molecular Targeted Therapy - standards Monoclonal antibodies Patients Primary Health Care - organization & administration Product development Canada United States United States > US
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	In Canada, 190,000 people are living with mild Alzheimer-type dementia and 532,000 to 799,000 people are living with amnestic mild cognitive impairment. Developing treatments for Alzheimer disease is challenging, with few effective therapies that only target symptoms. Although the US Food and Drug Administration approved aducanumab on Jun 7, 2021--the first new treatment for Alzheimer disease since 2003--its approval was controversial. Here, Watt et al examine the effectiveness of aducanumab for patients with Alzheimer disease.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0820-3946 1488-2329
DOI:	10.1503/cmaj.211134